Heartflow, Inc. (NASDAQ:HTFL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Heartflow, Inc. (NASDAQ:HTFL) has earned a consensus rating of “Moderate Buy” from the twelve analysts that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $43.4286.

Several research analysts have weighed in on the company. Robert W. Baird set a $45.00 price target on Heartflow in a research note on Friday. Morgan Stanley boosted their target price on shares of Heartflow from $35.00 to $40.00 and gave the stock an “equal weight” rating in a report on Friday. Stifel Nicolaus raised their target price on shares of Heartflow from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday. Wells Fargo & Company lifted their price target on shares of Heartflow from $37.00 to $39.00 and gave the company an “overweight” rating in a report on Friday. Finally, Weiss Ratings upgraded shares of Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, August 7th.

Insider Activity at Heartflow

In other Heartflow news, CEO John C.M. Farquhar sold 22,562 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $28.31, for a total transaction of $638,730.22. Following the completion of the transaction, the chief executive officer owned 436,280 shares in the company, valued at $12,351,086.80. This trade represents a 4.92% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 106,586 shares of company stock valued at $3,269,343 in the last quarter. 7.70% of the stock is currently owned by insiders.

Institutional Trading of Heartflow

Several hedge funds have recently made changes to their positions in the business. XXEC Inc. purchased a new position in shares of Heartflow in the 2nd quarter worth approximately $2,524,764,000. Wellington Management Group LLP boosted its stake in shares of Heartflow by 20.8% during the 4th quarter. Wellington Management Group LLP now owns 5,894,070 shares of the company’s stock worth $171,812,000 after purchasing an additional 1,014,006 shares during the period. BlackRock Inc. purchased a new stake in Heartflow in the 2nd quarter worth about $152,502,000. Bamco Inc. NY bought a new stake in Heartflow in the second quarter worth about $94,625,000. Finally, Jupiter Topco LLC purchased a new position in shares of Heartflow during the second quarter valued at approximately $70,983,000.

Heartflow Stock Performance

HTFL opened at $41.94 on Tuesday. The firm’s fifty day moving average is $29.35 and its 200 day moving average is $27.85. The stock has a market cap of $3.62 billion and a price-to-earnings ratio of -22.92. Heartflow has a fifty-two week low of $20.13 and a fifty-two week high of $43.28.

Heartflow (NASDAQ:HTFL) last released its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.15. The firm had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.50% and a negative net margin of 55.82%.The company’s quarterly revenue was up 47.7% compared to the same quarter last year. On average, equities research analysts predict that Heartflow will post -0.82 earnings per share for the current year.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.